CD40 and neoplasm: Early phase clinical trials of CD40 agonists in a variety of tumor settings have demonstrated activity, and additional clinical studies are needed to determine whether CD40 agonists can be added to the expanding repertoire of cancer drugs to either increase response (and preferably cure rates) in the frontline setting or to treat patients whose tumors have progressed on other frontline regimens.